Success Story: AI medical device software to quantify brain damage and clinical prognosis

NCC presenting the success story

The French NCC: CC-FR, dedicated to HPC, HPDA and AI technologies, brings together the community of technology providers and users. CC-FR federates the HPC, HPDA and AI ecosystem and supports SMEs on the use of intensive computing, high-performance data analysis and artificial intelligence.

Industrial Organisations Involved:

CC-FR, set up within the framework of EuroHPC, is managed by the European Pole of Competence in high performance digital simulation Teratec, in association with the European Center for Advanced Research and Training in Scientific Computing Cerfacs and with the participation of the Big National Equipment Intensive Computing  Genci.

Name and logo of the SME:

Name:  Braintale; Website:;

Technical/scientific Challenge:

BrainTale is an innovative company opening a new era in medicine by providing physicians with clinically validated prognostic solutions for the management of brain injured patients through sensitive and reliable measurements of brain white-matter microstructure alterations. Building on more than 15 years in clinical development, BrainTale’s products are developed collaboratively to address medical need and fulfil expectations of healthcare professionals and patients alike. Since its inception in 2018, the company has set up a complete quality management system and is now ISO:13485:2016 certified, with a suite of products available on the European market.


The use of the MYRIA supercomputer and the support of CC-FR allow Braintale to develop and prepare its AI-based digital medical device and product portfolio to improve health patients with neurological and resuscitating diseases.


Since fall 2021, Braintale has integrated the CC-FR Tailored program to benefit from high-level support in intensive computing. In collaboration with CRIANN (Centre Régional Informatique et

Digital Applications of Normandy), Braintale was able to access the MYRIA supercomputer, equipped with more than 10,000 computer cores very high-speed, and capable of executing nearly 600,000 billion transactions per second. This computing power has enabled the company to:

  • To analyse under efficient conditions the data of more than 500 patients in order to develop its research tools to optimize in charge of brain diseases
  • To optimize the retrospective analysis of large research cohorts that require intensive processing of very large volumes of data


The power and agility of MYRIA supercomputer combined with the company’s servers allow it to envisage a rapid commercial deployment of its solutions while increasing its product portfolio.


  • Keywords (Min 5): HPC, AI, HPDA, Algorithm, Health care, Medical devices

Industry sector: Health care / Pharmaceuticals / Medical devices

  • Technology: AI, HPDA, HPC


Dr Karim Azoum
+33 7 62 74 03 60

This project has received funding from the European High-Performance Computing Joint Undertaking (JU) under grant agreement No 951732. The JU receives support from the European Union’s Horizon 2020 research and innovation program and Germany, Bulgaria, Austria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, Ireland, Italy, Lithuania, Latvia, Poland, Portugal, Romania, Slovenia, Spain, Sweden, the United Kingdom, France, the Netherlands, Belgium, Luxembourg, Slovakia, Norway, Switzerland, Turkey, Republic of North Macedonia, Iceland, Montenegro